FGF23 and X-linked hypophosphatemia: The main findings from this real-world study show that in patients with confirmed XLH, burosumab improved serum phosphate levels and clinical outcomes, with baseline phosphate, PTH, and FGF23 levels predicting response, helping to guide personalized treatment.